Penumbra Stock News

Comerica Bank cut its holdings in Penumbra, Inc. (NYSE:PEN) by 1.7% in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 18,592 shares of the companys stock after selling 320 shares during the quarter. Comerica Bank owned about 0.05% of Penumbra worth $4,745,000 as of its most recent []

Equities research analysts expect Penumbra, Inc. (NYSE:PEN) to report earnings per share of $0.19 for the current quarter, Zacks reports. Three analysts have made estimates for Penumbras earnings, with the highest EPS estimate coming in at $0.24 and the lowest estimate coming in at $0.16. Penumbra posted earnings of $0.42 per share during the same []

Penumbra found using ticker (PEN) now have 6 analysts covering the stock with the consensus suggesting a rating of ''Strong_Buy''. The target price ranges between 350 and 308 calculating the mean target price we have 329.83. With the stocks previous close at 266.51 this would indicate that there is a potential upside of 23.8%. The 50 day MA is 272.53 while the 200 day moving average is 271.15. The company has a market capitalisation of $9,720m. Find out more information at: /> [stock_market_widget type="chart" symbol="PEN" chart="bar" range="6mo" interval="1d" line-color="rgb(49, 125, 189)"] Penumbra designs, develops, manufactures, and markets medical devices in the United States, Europe, Canada, Australia, and internationally. The company offers aspiration based thrombectomy systems and accessory devices, including revascularization device for mechanical thrombectomy, such as Penumbra System under the Penumbra JET, ACE, 3D Revascularization Device, and Penumbra ENGINE brands, as well as components and accessories; neurovascular embolization coiling systems to treat patients with various sizes of aneurysms and other neurovascular lesions under the Penumbra Coil 400, POD400, PAC400, and Penumbra SMART Coil brand names; and neurovascular access systems designed to provide intracranial access for use in a range of neurovascular therapies under the Neuron, Neuron MAX, Select, BENCHMARK, DDC, and PX SLIM brands.

Bank of America Corp DE cut its position in Penumbra, Inc. (NYSE:PEN) by 4.8% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 64,220 shares of the companys stock after selling 3,264 shares during the period. Bank of America Corp []

Related Stocks: ARGX , MGNX , CUTR , RNA , FULC , ITOS , TMO , PEN , TNYA , SGHT , AADI , RCOR , QDEL , TRIL , CHAQ , BCTG , ITMR , RACA ,

Comprehensive business-related information is covered in the Mechanical Thrombectomy Devices market report such as price level, market trend, demand, supply and price index. It provides only market related data. It does not include any personal data. Another main goal of

Penumbra, Inc. (PEN) CEO Adam Elsesser on Q3 2021 Results - Earnings Call Transcript

Penumbra (PEN) delivered earnings and revenue surprises of -14.29% and 4.93%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

New York, New York--(Newsfile Corp. - September 21, 2021) -  Pomerantz LLP is investigating claims on behalf of investors of Penumbra, Inc. ("Penumbra" or the "Company") (NYSE: PEN). Such investors a

NEW YORK, Sept. 20, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Penumbra, Inc. ("Penumbra" or the "Company") (NYSE: PEN).

NEW YORK, Sept. 13, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Penumbra, Inc. ("Penumbra" or the "Company") (NYSE: PEN).

NEW YORK, Sept. 5, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Penumbra, Inc. ("Penumbra" or the "Company") (NYSE: PEN).

New York, New York--(Newsfile Corp. - September 2, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Penumbra, Inc. ("Penumbra" or the "Company") (NYSE: PEN). Such investors are

ALAMEDA, Calif., Aug. 31, 2021 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the Morgan Stanley 19th Annual Global Healthcare Conferenc

NEW YORK, Aug. 30, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Penumbra, Inc. ("Penumbra" or the "Company") (NYSE: PEN). Such investors are advised to cont